M J Overman
Overview
Explore the profile of M J Overman including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
26
Citations
1220
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ambrosini M, Rousseau B, Manca P, Artz O, Marabelle A, Andre T, et al.
Ann Oncol
. 2024 May;
35(7):643-655.
PMID: 38777726
Background: POLE and POLD1 proofreading deficiency (POLE/D1pd) define a rare subtype of ultramutated metastatic colorectal cancer (mCRC; over 100 mut/Mb). Disease-specific data about the activity and efficacy of immune checkpoint...
2.
Maddalena G, Zeineddine F, Rivero-Hinojosa S, Aushev V, Chowdhury S, Zeineddine M, et al.
Ann Oncol
. 2024 May;
35(7):678-680.
PMID: 38734075
No abstract available.
3.
Andre T, Lonardi S, Wong K, Lenz H, Gelsomino F, Aglietta M, et al.
Ann Oncol
. 2022 Jun;
33(10):1052-1060.
PMID: 35764271
Background: In the phase II multicohort CheckMate 142 study, nivolumab plus low-dose (1 mg/kg) ipilimumab provided robust and durable clinical benefit with a manageable safety profile in previously treated patients...
4.
Bhamidipati D, Colina A, Hwang H, Wang H, Katz M, Fournier K, et al.
ESMO Open
. 2021 May;
6(3):100132.
PMID: 33940348
Background: Metastatic small bowel adenocarcinoma (SBA) has a poor prognosis. Due to its rarity, high-quality data are lacking to guide treatment. This retrospective analysis was conducted to help characterize the...
5.
Yoshino T, Pentheroudakis G, Mishima S, Overman M, Yeh K, Baba E, et al.
Ann Oncol
. 2020 Apr;
31(7):861-872.
PMID: 32272210
A Japan Society of Clinical Oncology (JSCO)-hosted expert meeting was held in Japan on 27 October 2019, which comprised experts from the JSCO, the Japanese Society of Medical Oncology (JSMO),...
6.
Bhamidipati D, Anand S, Gothwal A, Raghav K, Overman M
Ann Oncol
. 2019 Jan;
30(4):657-658.
PMID: 30698646
No abstract available.
7.
Parseghian C, Loree J, Morris V, Liu X, Clifton K, Napolitano S, et al.
Ann Oncol
. 2018 Nov;
30(2):243-249.
PMID: 30462160
Background: Colorectal cancer (CRC) has been shown to acquire RAS and EGFR ectodomain mutations as mechanisms of resistance to epidermal growth factor receptor (EGFR) inhibition (anti-EGFR). After anti-EGFR withdrawal, RAS...
8.
Overman M, Adam L, Raghav K, Wang J, Kee B, Fogelman D, et al.
Ann Oncol
. 2018 Jul;
30(3):495.
PMID: 29982323
No abstract available.
9.
Overman M, Adam L, Raghav K, Wang J, Kee B, Fogelman D, et al.
Ann Oncol
. 2017 Oct;
29(1):139-144.
PMID: 29069279
Background: Hypermethylation of promoter CpG islands [CpG island methylator phenotype (CIMP)] represents a unique pathway for the development of colorectal cancer (CRC), characterized by lack of chromosomal instability and a...
10.
Allenson K, Castillo J, San Lucas F, Scelo G, Kim D, Bernard V, et al.
Ann Oncol
. 2017 Jan;
28(4):741-747.
PMID: 28104621
Background: Exosomes arise from viable cancer cells and may reflect a different biology than circulating cell-free DNA (cfDNA) shed from dying tissues. We compare exosome-derived DNA (exoDNA) to cfDNA in...